![The sights of Paris Air Show Day 1 [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/IMG_1798-scaled-e1750092780492.jpg?#)
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression into the indication's standard of care.
Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression into the indication's standard of care.
